Search reports, ask a question, or jump to a page.
The problem
Intervention: Infant immunization with PCV20 or PCV15 compared to PCV13
Who it was tested with: Infants in 21 countries across Europe, Asia-Pacific, and the Americas.
The same group is measured before the intervention and again afterwards, with a baseline and an endline and sometimes a midline. Change is visible, but other causes cannot be ruled out.
"A multi-cohort, population-based model estimated the cumulative NNVs for infant programs with PCV20 and PCV15 relative to PCV13 in 21 countries. Outcomes included overall pneumococcal case, hospitalization, and death." The study uses mathematical modeling with probabilistic sensitivity analysis to compare vaccine programs, showing PCV20 provides superior public health impact over PCV15.
Model-based study relying on population disease estimates and serotype assumptions rather than direct clinical trial comparison; results' generalizability depends on accuracy of input parameters for each country.
Across countries and designs
12 studies · 20 countries
Published 18 Feb 2026
Classified by the Hub's AI
Not yet reviewed by a person. Model output is not AICS's view until reviewed.
claude-haiku-4-5-20251001 · synth-v1
